Why is "Atropine" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-26 11:36:49
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Atropine is a tropane alkaloid and anticholinergic medication used to treat certain types of nerve agent and pesticide poisonings as well as some types of slow heart rate, and to decrease saliva production during surgery. It is typically given intravenously or by injection into a muscle. Eye drops are also available which are used to treat uveitis and early amblyopia. The intravenous solution usually begins working within a minute and lasts half an hour to an hour. Large doses may be required to treat some poisonings.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Low-concentration atropine for management of myopia progression: does iris colour matter? - Nature
-
Myopia prevention as a standard of care: The role of low-dose atropine - Optometry Times
-
Case Report: Atropine-induced delirium in a dog - Frontiers
-
Insights into atropine usage - Ophthalmology Times Europe
-
University of Houston Co-Leads $25 Million NIH-Funded Grant to Study the Delay of Nearsightedness in Children - University of Houston
-
Application for Branded Atropine Drug Rejected by FDA - Review of Optometry
-
Q&A: Eye care practitioners urge FDA to approve low-dose atropine - Healio
-
Tapered atropine discontinuation reduces myopia rebound in children - Contemporary Pediatrics
-
FDA Denies Sydnexis Approval for Pediatric Myopia Treatment - Ophthalmology Advisor
-
Sydnexis's low-dose atropine shows strong phase 3 efficacy for pediatric myopia - Eyes On Eyecare
-
Efficacy and safety of orthokeratology sequentially combined with escalating atropine concentrations for myopia control in children - Nature
-
Study demonstrates 0.025% atropine balancing efficacy and tolerability in Chinese pediatric patients - Optometry Times
-
Low-dose Atropine Can Significantly Alter Binocular Vision - Review of Optometry
-
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment - Ophthalmology Times
-
FDA does not approve SYD-101 for slowing pediatric myopia - Healio
-
0.01% atropine combined with carteolol hydrochloride can inhibit the scleral remodeling in guinea pigs with form-deprivation myopia - Nature
-
BID Dosing of Atropine 0.01% Confers Significant Advantages in Myopia Control - Review of Optometry
-
Tapering Myopes Off Atropine Lessens Rebound Effect - Review of Optometry
-
Study Finds No Clear Benefit from Adding Atropine to HAL Lens Wear for Myopia - Review of Optometry
-
Continuous Use of 0.05% Atropine Significantly Slows Gamma Zone Enlargement - Review of Optometry
-
Neostigmine-Atropine Combination Triggered Stress Cardiomyopathy in a Healthy Patient: A Case Report and Literature Review - Cureus
-
Twice versus once daily application of 0.01% atropine for myopia control in children: a randomised controlled trial - Nature
-
Atropine Drops Not Tied to Ocular Issues in Kids With Myopia - Medscape
-
Santen begins European rollout of low-dose atropine for myopia in Germany - Optometry Times
-
Opinion | This drug treats myopia. I’m sick of telling patients they can’t have it. - The Washington Post
-
AAPOS: FDA’s nonapproval of SYD-101 ‘has important implications for pediatric eye care’ - Healio
-
Using Atropine for Cycloplegic Refraction May Avoid Overestimation of Premyopia in Children - Review of Optometry
-
Santen Receives UK Approval for Ryjunea® (low-dose atropine 0.1 mg/ml) to Slow Progression of Childhood Myopia - Yahoo Finance
-
UH, OSU researchers secure $25 million for trial assessing atropine drops and myopia management - Optometry Times
-
Cumulative Atropine Not Associated With Increased Risk of Ocular Events in Children With Myopia - The American Journal of Managed Care
-
No Link to Atropine in Higher Ocular Health Complications for Myopic Kids, Study Finds - Review of Optometry
-
FDA rejects Sydnexis’ NDA for low-dose atropine drop - Eyes On Eyecare
-
Atropine Use Linked to Lower Premyopia Prevalence in Preschool-Aged Children - Optometry Advisor
-
Study of atropine drops for delaying myopia onset receives $25 million in NIH grants - Healio
-
EyeWorld Weekly, March 27, 2026 - EyeWorld
-
Astraya unveil ‘A Theory of Time’ as second preview of ‘Atropine’ - SIDE-LINE
-
Response of accommodation and vergence systems to low dose atropine - Wiley Online Library
-
3-year results of 0.01% and 0.1% loading dose atropine treatment including washout in Danish children with myopia: a placebo-controlled, randomised clinical trial - British Journal of Ophthalmology
-
Study: 0.04% Atropine Outperforms Ortho-K and 0.01% Atropine for Myopia Control - Review of Optometry
-
National trial to test preventative atropine drops for pediatric myopia - Eyes On Eyecare
-
Study: Better myopia control seen with ortho-K lenses, atropine - Healio
-
EyeWorld Weekly, November 7, 2025 - EyeWorld
-
Atropine vs spectacles: Which move will be more powerful in the game of myopia management? - Optometry Times
-
In the Eye of the Beholder: Mixed Results From Study of the Risks of Atropine Drops for Myopia in Children - Managed Healthcare Executive
-
Sydnexis releases phase 3 STAR trial results on SYD-101 0.01% for slowing myopia progression - Optometry Times
-
Treating myopia today: US-focused treatments, challenges, and global insights - Ophthalmology Times
-
Long-term atropine use to treat myopia associated with increased risk of ocular complication in schoolchildren in Taiwan - Optometry Times
-
Atropine, Ortho-K Combo Enhances Myopia Control Outcomes - Review of Optometry
-
Meta-analysis Shows Myopia Control Interventions Increase Choroidal Thickness - Review of Optometry
-
Study seeks to determine best way to treat myopia in children - Vanderbilt Health News
-
European Commission approves low-dose atropine eye drop Ryjunea, Santen announces - Optometry Times
-
Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine - British Journal of Ophthalmology
-
Atropine Drops for Vitreous Floaters Show Promise as Less Invasive Alternative - MedPage Today
-
Company founded by Mercer professors wins award for heart treatment breakthrough - Mercer University
-
Low-Dose Atropine Drops: Safe Treatment for Floaters | ASRS 2025 - Managed Healthcare Executive
-
Ophthalmology entering age of topical eye drops for refractive correction - Healio
-
The Dos and Don’ts of Switching Therapy - Review of Optometry
-
ARVO 2025: 12-month results in myopic children using combination treatment of atropine and DIMS spectacle lenses - Ophthalmology Times
-
Low-dose atropine eyedrops no better than placebo for slowing myopia progression - National Institutes of Health (.gov)
-
Atropine Sulfate Market Analysis By Application, Type, - openPR.com
-
MHRA approves low-dose atropine eye drops for slowing myopia progression - Association of Optometrists (AOP)
-
Meta-analysis Proposes Red-light Therapy as Most Effective Myopia Control Option - Review of Optometry
-
Diversified Segmental Defocus Optimization Lenses Aid Myopia Prevention - Ophthalmology Advisor
-
Changes in the Ocular Surface and Meibomian Glands Following Administration of 0.01% and 0.02% Atropine - Frontiers
-
A multicenter Spanish study of atropine 0.01% in childhood myopia progression | Scientific Reports - Nature
-
Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia - Nature
-
Graduated atropine protocol effects on spherical equivalent and axial length in premyopic children - Nature
-
Low-Dose Atropine Eye Drops Under Review for Pediatric Myopia - Ophthalmology Advisor
-
Low-dose atropine causes esotropia in patient case - Ophthalmology Times
-
Efficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response - Nature
-
Evaluating the effect of 0.125% atropine on foveal microvasculature using optical coherence tomography angiography - Nature
-
Sydnexis reports phase 3 topline data on SYD-101 eye drop for pediatric myopia - Eyes On Eyecare
-
Evaluation of Acute Irinotecan-Related AEs at 2 Different Infusion Rates in Patients With Gastrointestinal Malignancies - Journal of Hematology Oncology Pharmacy
-
Low-Dose Atropine Slows Myopia Progression in Children, finds Phase 3 STAR Trial - Medical Dialogues
-
Professor Nicola Logan provides an update on atropine - Association of Optometrists (AOP)
-
Age-related results over 2 years of the multicenter Spanish study of atropine 0.01% in childhood myopia progression - Nature
-
Repeated low-level red-light therapy vs. conventional treatments for myopic control in children: a systematic review and meta-analysis - Nature
-
Pediatrics board addresses low-dose atropine treatment, myopia progression - Healio
-
Atropine augments cardiac contractility by inhibiting cAMP-specific phosphodiesterase type 4 - Nature
-
Comparison of the long-term effects of atropine in combination with Orthokeratology and defocus incorporated multiple segment lenses for myopia control in Chinese children and adolescents - Nature
-
Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial - Nature
-
Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial - Nature
-
Update in myopia and treatment strategy of atropine use in myopia control - Nature
-
Which Matters More: Reducing Axial Length or Refractive Error Progression? - Review of Optometry
-
Atropine instillation after glaucoma surgery may impair vision, prolong rehabilitation time - Ophthalmology Times Europe
-
Efficacy of 0.01% low dose atropine and its correlation with various factors in myopia control in the Indian population - Nature
-
ARVO 2025: Barsha Lal, PhD, presents an atropine study that addresses families' accomodative concerns - Ophthalmology Times
-
Characteristics of responders to atropine 0.01% as treatment in Asian myopic children - Nature
-
EMA grants positive CHMP opinion for low-dose atropine SYD-101 (Ryjunea, Sydnexis) - Ophthalmology Times Europe
-
The Lowdown on Low-dose Atropine - Review of Optometry
-
ENTOD Pharmaceuticals announces CDSCO approval of 0.05% atropine drops (Myatro XL) - Ophthalmology Times Europe
-
Ethnicity, Eye Color May Impact Atropine Efficacy - Review of Optometry
-
FDA accepts NDA for low-dose atropine from Sydnexis - Optometry Times
-
A Whiff of Garlic, a Turn of Fate: Recognizing Organophosphorus Poisoning Amid Diagnostic Uncertainty: A Case Report - Wiley Online Library
-
Low concentration atropine and myopia: a narrative review of the evidence for United Kingdom based practitioners - Nature
-
A comparative study of orthokeratology and low-dose atropine for the treatment of anisomyopia in children - Nature
-
LAMP Study: Atropine 0.05% Effective For Myopia Control at Five Years - Review of Optometry
-
Risk factors for rapid axial length elongation with low concentration atropine for myopia control - Nature
-
Study Finds Combination of MiSight, 0.05% Atropine Slows Myopia Progression by 0.38D - Review of Optometry
-
Additive effect of atropine eye drops and short-term retinal defocus on choroidal thickness in children with myopia - Nature
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.